Velan Capital, L.P. insider trades: Progenics Pharmaceuticals (PGNX) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Velan Capital, L.P. reports to the SEC
Open-market buys and sales
3 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Sep 9, 2019 | PGNX | ↑ Buy | 72,023 | $4.99 | $360K | Direct | Sep 11, 2019 (2d) |
| Sep 4, 2019 | PGNX | ↑ Buy | 521,038 | $4.45 | $2.3M | Direct | Sep 5, 2019 (1d) |
| Aug 26, 2019 | PGNX | ↑ Buy | 204,056 | $4.31 | $879K | Direct | Aug 27, 2019 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Velan Capital, L.P.'s insider trades
Velan Capital, L.P. is a 10% owner of Progenics Pharmaceuticals (PGNX). Since Aug 26, 2019, it has reported 3 open-market purchases worth $3.6M and no sales on SEC Form 4. There have been no open-market trades in the last 12 months.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every PGNX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.